Showing 5,601 - 5,620 results of 106,501 for search '(( 5 ((a decrease) OR (nn decrease)) ) OR ( 50 ((we decrease) OR (mean decrease)) ))', query time: 1.07s Refine Results
  1. 5601
  2. 5602
  3. 5603
  4. 5604

    Analysis of AMPA-R mediated EPSCs (aEPSCs) at CA1 synapses in hippocampal slices from P10 mice ICV injected at P1, P3, and P5 with saline or GR1. by Nicole M. Lykens (3727072)

    Published 2017
    “…<b>(d)</b> Rectification index of aEPSC amplitude was moderately decreased after SMO treatment (n = 8; p = 0.017). …”
  5. 5605

    Loss of Fmrp leads to decreased neuronal differentiation but increased astrocyte differentiation. by Yuping Luo (147790)

    Published 2010
    “…Data are presented as mean ± SEM; *, p<0.05, **, p<0.01, ***, p<0.01, Student's t-test.…”
  6. 5606
  7. 5607
  8. 5608
  9. 5609
  10. 5610

    Decreased branching, partial right isomerization and epithelial proximalization in CKO lungs. by Stijn P. De Langhe (38981)

    Published 2008
    “…<p>(a–d) β-gal staining of <i>Dermo1<sup>Cre/+</sup>/Rosa26R</i> WT lungs at E11.5 and E13.5 reports Cre recombination activity in the mesenchyme of the embryonic lung. …”
  11. 5611
  12. 5612

    Local inhibition of nitrergic activity in tenotomized rats accelerates muscle regeneration by increasing fiber area and decreasing central core lesions by A.D. Seabra (6515330)

    Published 2019
    “…<div><p>Muscular atrophy is a progressive degeneration characterized by muscular proteolysis, loss of mass and decrease in fiber area. …”
  13. 5613
  14. 5614
  15. 5615
  16. 5616

    The estrogen receptor-α agonist PPT decreases cardiac myofilament activation. by Justyna Kulpa (313372)

    Published 2013
    “…<p>Myocardium was treated with the estrogen receptor-α agonist PPT (100 nM) for 1 (A) (N = 9), 2.5 (B) (N = 9), or 5 min (C) (N = 22). …”
  17. 5617
  18. 5618

    P63 and CD44 expression were decreased in triple mutants. by Kyung-Suk Choi (162073)

    Published 2012
    “…Np63 was expressed in the AER and epithelial cells of E10.5 and E11.5 control (A and C) and triple mutant hindlimbs (B and D). …”
  19. 5619

    Identification of a Hydroxypyrimidinone Compound (<b>21</b>) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure by Wei Meng (505670)

    Published 2021
    “…Due to the increased polarity at C2, the permeability for these compounds decreased. Further adjustment of the polarity by replacing the N1 2,6-dimethoxyphenyl group with a 2,6-diethylphenyl group and reoptimization for the potency of the C5 pyrroloamides resulted in potent compounds with improved permeability. …”
  20. 5620

    Identification of a Hydroxypyrimidinone Compound (<b>21</b>) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure by Wei Meng (505670)

    Published 2021
    “…Due to the increased polarity at C2, the permeability for these compounds decreased. Further adjustment of the polarity by replacing the N1 2,6-dimethoxyphenyl group with a 2,6-diethylphenyl group and reoptimization for the potency of the C5 pyrroloamides resulted in potent compounds with improved permeability. …”